Summary of Dyne Therapeutics 2026 Conference Call Company Overview - **Company**: Dyne Therapeutics (NasdaqGS:DYN) - **Focus**: Transitioning to a fully integrated biotech company with a focus on rare diseases, particularly Duchenne Muscular Dystrophy (DMD) and Myotonic Dystrophy Type 1 (DM1) [1][2] Key Points and Arguments 2026 Outlook - 2026 is anticipated to be a breakout year for Dyne, with significant validation of its platform and products [2] - The company aims to transition from clinical validation to commercial operations, with key milestones including the completion of REC for DM1 enrollment and filing for BLA for DMD [3] Product Pipeline - Dyne plans to have eight products in the clinic over the next few years, including DMD, DM1, FSHD, and Pompe [4][48] - The company has a strong platform that allows for expansion into multiple exons in DMD and other diseases [4] DMD Program Highlights - The drug DYNE-251 for DMD has shown positive top-line results, demonstrating sustained functional improvement and significant increases in dystrophin expression [6][7] - The DELIVER study reported a sevenfold improvement in dystrophin expression compared to the standard of care, with functional improvements across six endpoints [9][10] Regulatory Environment - Dyne has Breakthrough Therapy designation, which facilitates more frequent interactions with the FDA [12] - The company believes it has a strong submission package for accelerated approval, supported by a large data set and a placebo-controlled study design [12][13] Commercial Strategy - Dyne is preparing for the launch of its products by building a team with significant rare disease launch experience and establishing a well-defined market strategy [22][24] - The company aims to leverage existing reimbursement structures and strong patient advocacy to ensure a successful launch [24][25] Future Growth and Exon Development - The development of other exons is seen as a key component of Dyne's growth strategy, with high excitement for the potential of these products [27][29] - The FORCE platform is expected to facilitate faster development of these exons due to its established chemistry and mechanisms [30][52] Confirmatory Study for DM1 - Dyne is firming up its confirmatory study for DM1, using Five Times Sit to Stand as a primary endpoint, which aligns with FDA expectations [35][36] - The study is designed to show broad functional improvement and is fully powered for statistical significance [36] Competitive Landscape - Dyne differentiates itself from competitors by focusing on a unique mechanism of action and a robust safety profile, with no significant anemia reported compared to placebo [44][45] Additional Important Information - The company expects to complete enrollment for the REC cohort in the second quarter of 2026, with data reporting anticipated in the first quarter of 2027 [57][58] - Dyne emphasizes the importance of a well-prepared launch and the potential for capital-efficient operations due to the concentration of patients in a limited number of muscle centers [24][25] This summary encapsulates the key insights and strategic direction of Dyne Therapeutics as discussed in the conference call, highlighting the company's focus on innovation, regulatory strategy, and market preparation.

Core Insights - Vertex Pharmaceuticals announced positive Week 36 interim analysis results from the RAINIER Phase 3 trial of povetacicept for IgA nephropathy, achieving significant reductions in proteinuria and serum Gd-IgA1 levels compared to placebo [1][2][3] Efficacy Results - The primary endpoint showed a 52.0% reduction in proteinuria (UPCR) from baseline, with a statistically significant 49.8% reduction compared to placebo (P<0.0001) [1][2] - For the first secondary endpoint, povetacicept treatment resulted in a 77.4% reduction in serum Gd-IgA1, leading to a 79.3% reduction compared to placebo (P<0.0001) [1][2] - In patients with baseline hematuria, 85.1% achieved hematuria resolution, a 61.7% improvement compared to placebo (P<0.0001) [1][2] Safety Profile - Povetacicept was generally safe and well tolerated, with most adverse events being mild to moderate [1][2] - Serious adverse events were low, with 3.0% in the povetacicept group and 4.3% in the placebo group [2] - Treatment discontinuation rates were 3.8% for povetacicept and 8.8% for placebo [1][2] Regulatory and Development Plans - Vertex plans to complete the Biologics License Application (BLA) for povetacicept by the end of March for potential U.S. Accelerated Approval [1][2] - The FDA has granted rolling review for the BLA, which Vertex is expediting using a priority review voucher [2][3] - The RAINIER trial will continue with final analysis expected at two years of treatment, focusing on total estimated glomerular filtration rate (eGFR) slope [2][3] About Povetacicept - Povetacicept is a dual inhibitor of BAFF and APRIL cytokines, showing improved binding affinity and potency compared to other inhibitors in preclinical studies [2][3] - It has received FDA Breakthrough Therapy Designation for IgA nephropathy and is the only dual BAFF+APRIL inhibitor in pivotal trials for multiple kidney diseases [2][3] About IgA Nephropathy - IgA nephropathy is a serious kidney disease affecting approximately 330,000 people in the U.S. and Europe, with a significant risk of progression to end-stage renal disease [2][3]

Summary of REGENXBIO Conference Call Company Overview - **Company**: REGENXBIO (NasdaqGS: RGNX) - **Industry**: Gene Therapy, specifically focusing on treatments for Duchenne Muscular Dystrophy (DMD) and ophthalmology-related diseases Key Points Regulatory and Development Updates - REGENXBIO is preparing for a pre-BLA (Biologics License Application) meeting with the FDA regarding the RGX-202 program, focusing on the relationship between microdystrophin and functional benefit [4][5] - The company has gained access to new natural history data and methods to compare data, which will be discussed in the upcoming FDA meeting [5] - Concerns about the accelerated approval pathway have been noted, but the company remains optimistic about its applicability to their program [6] Manufacturing Capabilities - REGENXBIO has invested in manufacturing processes for biologics, achieving high yields (80% full capsid) and purity in their products [10] - The Rockville plant can produce 2,500 doses per year, with full control over manufacturing processes, which positions the company well for potential approval in 2027 [11] Commercial Strategy - Pricing strategy for DMD treatments is still under consideration, but the company expects to align with existing commercial products based on safety and efficacy data [14] - The market for DMD treatments has expanded, and REGENXBIO believes it can capture a significant share due to its manufacturing capabilities and product profile [19] Global Market Access - The company plans to leverage accelerated approval to access international markets quickly, potentially through named patient sales [24] - A partnership approach is considered essential for entering markets outside the U.S., as REGENXBIO lacks a sales force in Europe [25] Ophthalmology Developments - REGENXBIO anticipates a $100 million milestone from AbbVie for early dosing in diabetic eye disease, which will support cash flow [32] - The company is optimistic about the potential of its subretinal and suprachoroidal delivery methods for treating conditions like wet AMD and diabetic retinopathy, with expectations of capturing a significant market share [39][40] MPS Programs and Regulatory Challenges - The company is addressing a clinical hold on RGX-111 and RGX-121 and is confident in resolving the issues within months [44] - Discussions with the FDA regarding the approval of RGX-121 are ongoing, focusing on the biomarker D2S6 and the classification of treated patients as neuronopathic [46][52] Financial Considerations - REGENXBIO views the potential for Priority Review Vouchers (PRVs) as a significant non-dilutive financing opportunity, with three programs eligible for PRVs [57][61] - The company is focused on maintaining a strong cash runway into 2027, which includes anticipated milestones from partnerships [32][62] Future Pipeline and Strategic Focus - While 95% of spending is directed towards late-stage programs, REGENXBIO is also developing new capsid technologies for future applications, including dry AMD [66] Additional Insights - The company is positioned to capitalize on the growing market for gene therapies, particularly in rare diseases, and is actively working to enhance its product offerings and market presence [62][66]

Financial Data and Key Metrics Changes - REGENXBIO ended the quarter on December 31, 2025, with cash equivalents and marketable securities of $241 million, a slight decrease from $245 million as of December 31, 2024 [18] - R&D expenses increased to $228 million for the year ended December 31, 2025, compared to $209 million in 2024, primarily due to pivotal trial execution and manufacturing costs [19] - Total annual revenue was reported at $170 million, which includes upfront license revenue and an increase in royalty revenue [19][20] Business Line Data and Key Metrics Changes - The RGX-202 program for Duchenne muscular dystrophy (DMD) showed strong enrollment and positive functional outcomes, with an average improvement of 7.4 compared to the recognized CTAP model at 18 months [11][12] - The RGX-314 franchise for wet AMD and diabetic retinopathy is advancing, with enrollment completed in pivotal studies ATMOSPHERE and ASCENT, and a 93% reduction in annualized anti-VEGF injection need reported [14][15] - The NAVIGATE pivotal study for diabetic retinopathy is set to begin patient dosing next quarter, triggering a $100 million milestone from AbbVie [9][15] Market Data and Key Metrics Changes - The company is focusing on large indications such as Duchenne, wet AMD, and diabetic retinopathy, which represent significant commercial opportunities [22] - The unmet need in the Duchenne community remains significant, with less than 1% of the global population having received an approved gene therapy [7] Company Strategy and Development Direction - REGENXBIO aims to transition from a late-stage development organization to a commercial entity by advancing its late-stage pipeline and focusing on execution [6][22] - The company is committed to addressing clinical holds for RGX-111 and RGX-121 while continuing to support the MPS community [10][21] - The strategy includes leveraging in-house manufacturing and partnerships to enhance the treatment landscape [22] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the upcoming pivotal readouts and the potential for accelerated approval pathways for RGX-202 [5][26] - The company is optimistic about its safety profile and the compelling data from its clinical trials, which are expected to support its regulatory submissions [28][37] - Management acknowledged the importance of ongoing dialogue with the FDA to ensure alignment on data analysis methods and submission expectations [90] Other Important Information - The company has received clinical hold letters for RGX-111 and RGX-121 but believes the requirements to remove the holds are addressable [9] - REGENXBIO's cash runway is expected to extend into early 2027, not including anticipated milestones and additional funds from collaborations [20][21] Q&A Session Summary Question: Concerns about control trials for DMD - Management expressed confidence in the design of the confirmatory study and the compelling data supporting their approach to accelerated approval [25][26] Question: Potential longer duration follow-up for FDA - Management indicated that they would have 12-month data on the pivotal dataset and that the confirmatory study would provide additional safety data [35][36] Question: Update on RGX-202 data presentation - Management confirmed that the upcoming presentation would include additional functional data and safety outcomes [60][61] Question: Safety profile for DMD - Management reported no cases of liver injury or thrombocytopenia in the RGX-202 study, highlighting a differentiated safety profile compared to existing therapies [69] Question: Heparan sulfate data in MPS I - Management acknowledged the importance of heparan sulfate measurements and indicated that they would provide more detailed results in response to the CRL [81][82]

Financial Data and Key Metrics Changes - REGENXBIO ended Q4 2025 with cash equivalents and marketable securities of $241 million, a slight decrease from $245 million at the end of 2024, reflecting cash used for operating activities despite significant upfront payments and royalty monetization [17] - R&D expenses increased to $228 million for the year ended December 31, 2025, compared to $209 million in 2024, primarily due to pivotal trial execution and manufacturing costs [18] - Total annual revenue for 2025 was $170 million, including upfront license revenue and increased royalty revenue from Zolgensma and Evrysdi [18] Business Line Data and Key Metrics Changes - The RGX-202 program for Duchenne muscular dystrophy (DMD) showed robust enrollment and positive safety and efficacy data, with an average improvement of 7.4 points in the NSAA compared to the CTAP model at 18 months [10][11] - The RGX-314 franchise for wet AMD and diabetic retinopathy is advancing, with enrollment completed in pivotal studies ATMOSPHERE and ASCENT, and a 93% reduction in annualized anti-VEGF injection need reported [12][13] - The company is addressing clinical holds for RGX-111 and RGX-121, with plans to resubmit the BLA after addressing the requirements [8][9] Market Data and Key Metrics Changes - The company is entering pivotal phase IIb/III programs for diabetic retinopathy in collaboration with AbbVie, with first patient dosing expected next quarter [8] - Top-line data for subretinal Surrovac in wet AMD is anticipated in Q4 2026, which would mark the first gene therapy for this indication if approved [12] Company Strategy and Development Direction - REGENXBIO aims to transition from a late-stage development organization to a commercial entity, focusing on executing key milestones and advancing its late-stage pipeline [4][20] - The company is committed to addressing unmet needs in rare diseases, particularly in the Duchenne and MPS communities, and is investing in in-house manufacturing capabilities [20][21] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the upcoming pivotal readouts and the potential to enhance treatment landscapes for DMD, wet AMD, and diabetic retinopathy, which represent significant commercial opportunities [20] - The company is preparing for discussions with the FDA regarding its BLA submission strategy, emphasizing the importance of functional data in supporting its case [30][31] Other Important Information - The company received a $100 million milestone payment from AbbVie upon first patient dosing in the NAVIGATE study, which is expected to extend its cash runway into the second half of 2027 [19] - Management highlighted the importance of ongoing dialogue with the FDA to ensure alignment on data analysis methods and regulatory expectations [87] Q&A Session Summary Question: Concerns about controlled trials for DMD - Management expressed confidence in the study design and FDA engagement, noting that the protocol was reviewed and approved by the FDA, and emphasized the compelling data from older patients [25][26] Question: Duration follow-up for safety in DMD - Management indicated that the confirmatory study would provide additional safety data, and they are prepared to discuss this with the FDA [34] Question: Moving forward with RGX-314 - Management clarified that the decision to proceed with Dose Level 3 was based on compelling results and safety data, and they are continuing to evaluate higher doses for wet AMD [41][44] Question: Functional data expectations - Management stated that they expect to provide top-line functional data for approximately seven patients at the 12-month mark, emphasizing the importance of this data for regulatory discussions [51][52] Question: Heparan sulfate data in MPS I - Management confirmed that they have been measuring heparan sulfate and will provide detailed results in response to the CRL, emphasizing the importance of this biomarker in their discussions with the FDA [78][79]

Financial Data and Key Metrics Changes - The company ended 2025 with cash and cash equivalents of $13.2 million, down from $23.3 million as of December 31, 2024 [7] - Net loss for the full year 2025 was $21.8 million or $8.35 per basic and diluted share, compared to a net loss of $44.6 million or $36.52 per basic share and $41.89 per diluted share in 2024 [9] - Research and development expenses for Q4 2025 were approximately $11.5 million, a decrease from approximately $26.6 million for the year ended December 31, 2024 [8] Business Line Data and Key Metrics Changes - The company advanced its lead asset, Iopofosine I 131, and is on track to submit a conditional marketing authorization application in Q3 2026 [4] - CLR 125, a new asset for triple-negative breast cancer, has initiated a phase 1b study, with early interim data expected in mid-2026 [5][6] - The company raised approximately $15.2 million throughout the year, extending its cash runway for ongoing pipeline advancements [7] Market Data and Key Metrics Changes - The European market for the second line setting is estimated to be over 12,000 patients, slightly higher than the U.S. market, which is just below 12,000 patients [54] - The conditional marketing authorization in Europe is expected to target a third line or later post-BTKI patient population, with plans to shift to a second line setting upon completion of the confirmatory study [54][55] Company Strategy and Development Direction - The company is focused on advancing its regulatory position in both Europe and the U.S. for Iopofosine I 131, with a clear strategy for market approval [4][10] - Strengthening supply chain infrastructure and expanding the global intellectual property estate are key components of the company's strategy [6][7] - The company aims to deliver transformative therapies to patients with difficult-to-treat cancers, supported by robust science and regulatory engagement [17] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the regulatory paths for Iopofosine I 131, highlighting the strength of the clinical data and the unmet medical need [5][10] - The company anticipates a milestone-rich 2026, with multiple value-creating milestones expected throughout the year [17] - Management noted high interest from physicians and patients in participating in upcoming trials, indicating a strong market demand for their therapies [41][42] Other Important Information - The company has made significant progress in its clinical development pipeline, including the initiation of new studies and strengthening partnerships for isotope supply [6][16] - The company has expanded its global patent estate, providing long-term protection for its key assets [6] Q&A Session Summary Question: Can the same submission package for EMA be used for FDA? - Management confirmed that while the formats differ, much of the data is similar and can be applied to both submissions [22][23] Question: What is the expected timeline for FDA submission post-initiation of the confirmatory study? - Management indicated that they expect to submit the NDA to the FDA about one to two months after initiating the study, with a response expected within 7 to 9 months [25][27] Question: What is the expected progression-free survival (PFS) compared to standard care? - Management provided insights into historical data, indicating that the median PFS for standard therapies is around 8 months, and they expect Iopofosine to perform better based on their data [29][40] Question: What are the plans for distribution in Europe? - The company plans to partner with various parties for commercialization in Europe, with a unique competitive advantage due to the longer shelf life of their product [53][54]

Summary of Entrada Therapeutics FY Conference Call Company Overview - **Company**: Entrada Therapeutics (NasdaqGM:TRDA) - **Event**: 46th Annual TD Cowen Healthcare Conference - **Date**: March 03, 2026 Key Points Industry and Market Context - **Duchenne Muscular Dystrophy (DMD) Market**: Estimated at $5 billion in the U.S. with limited competitive penetration and significant unmet clinical needs [4][14] - **Myotonic Dystrophy Type 1 (DM1)**: Partnership with Vertex, with potential access to up to $485 million in milestones [6][19] - **Inherited Retinal Diseases (IRDs)**: Addressing a high unmet clinical need with no approved therapeutics for conditions like Usher syndrome type 2A [20][21] Clinical Pipeline and Milestones - **DMD Programs**: - Four potential clinical readouts expected in 2026 from exon 44 and exon 45 studies [2][3] - First cohort data for ENTR-601-44 expected in Q2 2026, with a second cohort by year-end [7][23] - Aiming for double-digit dystrophin production in the first cohort [30][31] - **DM1 Program**: Vertex's VX-670 is in a Phase I/II study, with dosing completion expected in mid-2026 [20][19] - **Ocular Disease Programs**: ENTR-801 targeting Usher syndrome type 2A, with IND-enabling studies planned [21][22] Financial Position - **Cash Runway**: Approximately $296 million available until Q3 2027 [5][24] - **Funding Strategy**: Focus on non-dilutive capital through partnerships, exemplified by the Vertex collaboration [51] Strategic Focus - **Differentiation and De-risking**: Emphasis on creating best-in-class therapeutics through innovative delivery mechanisms like endosomal escape vehicles (EEVs) [11][50] - **Regulatory Strategy**: Plans for Accelerated Approval in the U.S. based on clinical data from ex-U.S. studies [14][35] Competitive Landscape - **Comparison with Competitors**: Aiming to surpass competitors like Avidity and Sarepta in dystrophin production levels [13][44] - **Market Opportunity**: Targeting approximately 30,000 patients in the U.S. and Europe with DMD, with a focus on capturing a significant market share [14][15] Research and Development - **Clinical Study Design**: Studies designed to establish safety and functional benefits, with a focus on long-term patient outcomes [41][42] - **Combination Therapies**: Potential for future combination therapies with gene therapy, depending on market dynamics and payer considerations [38] Future Outlook - **2026 as a Transformational Year**: Anticipated significant clinical data and potential regulatory milestones across DMD, DM1, and IRDs [2][24] - **Pipeline Expansion**: Continued development of next-generation oligonucleotides and EEVs for various diseases [24][50] Additional Insights - **Collaboration with Vertex**: Clear delineation of responsibilities and effective communication have been key to the success of the partnership [48] - **Focus on Patient Outcomes**: Commitment to developing therapeutics that improve the quality of life for patients, with a strong emphasis on safety and efficacy [42][39]

Summary of uniQure FY Conference Call - March 02, 2026 Company Overview - **Company**: uniQure (NasdaqGS:QURE) - **Focus**: Gene therapies for neurodegenerative diseases, particularly Huntington's disease and epilepsy Key Points on Huntington's Disease Program (AMT-130) - **Phase 3 Data**: The pivotal phase 1/2 trial showed a 75% slowing of disease progression at three years, measured by the composite Unified Huntington's Disease Rating Scale (UHDRS) [9] - **Total Functional Capacity**: A 60% decline in disease progression was observed, which is significant for FDA approval [9] - **Neurofilament Light**: A decrease from baseline was noted, contrasting with the expected 10%-15% annual increase in neurodegeneration markers [9] - **FDA Interactions**: The FDA granted RMAT designation in early 2024 based on initial data, but later expressed concerns about the Phase 1/2 study being hypothesis-generating and not suitable for BLA submission [15][20] - **Next Steps**: A Type B meeting with the FDA is planned to discuss phase 3 study design and the use of external controls [44][46] - **Patient Community Support**: Strong advocacy from patient groups has been noted, with significant engagement in policy discussions and petitions to the FDA [82][84] Key Points on AMT-260 (Temporal Lobe Epilepsy Program) - **Initial Data**: A case study showed a 92% reduction in seizure frequency in the first patient treated, with no significant adverse events reported [84] - **Current Status**: Six patients have been dosed in the first cohort, with data expected in the second quarter of 2026 [85] - **Future Goals**: Aiming for a 50% or higher reduction in seizures to support progression to pivotal trials [96] Key Points on AMT-191 (Fabry Disease Program) - **Study Progress**: A Phase I/II study is ongoing with 11 patients treated, all of whom are off enzyme replacement therapy [99] - **Outcomes**: Dose-dependent increases in the deficient enzyme have been observed, with ongoing monitoring for long-term outcomes [99] Financial and Strategic Considerations - **Funding Position**: The company has a strong balance sheet with a runway into the second half of 2029, allowing for continued investment in promising programs [104] - **Partnership Strategy**: The company remains open to partnerships but emphasizes the need for data to support investment decisions [105] Safety Profile - **AMT-130 Administration**: The procedure is reported to be safe and well-tolerated, with most adverse events being procedure-related rather than drug-related [64] Regulatory Landscape - **International Engagement**: The company is engaging with regulators outside the U.S. for potential expedited reviews and expanded access pathways [71][74] Conclusion - **Commitment to Patients**: The company is focused on advancing its therapies while ensuring ethical considerations in study designs, particularly for slow-progressing diseases like Huntington's [46][54]

Summary of Disc Medicine Conference Call - February 17, 2026 Company Overview - **Company**: Disc Medicine (NasdaqGM:IRON) - **Focus**: Development of bitopertin for the treatment of Erythropoietic Protoporphyria (EPP) Key Points Regulatory Update on Bitopertin - **Complete Response Letter (CRL)**: Received from the FDA indicating uncertainty about whether the reduction in protoporphyrin IX (PP9) is likely to predict clinical benefit, despite acknowledging significant PP9 reduction [2][9] - **Commitment to Approval**: Company remains committed to advancing bitopertin and believes the issues raised in the CRL can be addressed with ongoing Phase 2 APOLLO study results expected in Q4 2026 [3][10] APOLLO Trial Details - **Trial Design**: Randomized, double-blind trial measuring both PP9 reduction and improvement in sunlight tolerance as co-primary endpoints [11] - **Enrollment Status**: High enthusiasm with full enrollment expected by March 2026, ahead of schedule [10] - **Statistical Significance**: Both co-primary endpoints need to achieve a p-value of 0.05 for approval [24] Clinical Data and Efficacy - **AURORA Study Results**: Achieved primary endpoint of PP9 reduction with high statistical significance; evidence of improvement in clinical benefits noted [5][15] - **Phototoxic Events**: Significant reduction in phototoxic reactions observed in the 60 mg dose group, with complete elimination during the second half of the study [6] Future Steps and Timeline - **Type A Meeting**: Planned to discuss the approach for resubmission and response to the CRL [16] - **NDA Resubmission**: Expected to occur by the end of 2026, with a six-month review period leading to a potential FDA decision in mid-2027 [19] Financial Outlook - **Funding Status**: Company is in a strong financial position, with cash runway projected into 2029, allowing continued investment in R&D programs [20] Other Programs - **DISC-0974**: Additional data from Phase 2 myelofibrosis study expected in the second half of 2026 [19] - **DISC-3405**: Initial data from Phase 2 study in Polycythemia Vera anticipated soon, with rapid trial enrollment noted [20] Patient Impact and Advocacy - **Patient Stories**: Highlighted the transformative impact of bitopertin on patients' lives, emphasizing the company's mission to support the EPP community [9][17] Conclusion - **Company's Position**: Despite the setback with the CRL, the company expresses confidence in the APOLLO trial and the potential of bitopertin to set a new standard of care for EPP patients [16][21]

As filed with the Securities and Exchange Commission on December 16, 2025 Registration No. 333-291852 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 Amendment No. 1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Edison Oncology Holding Corp. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Nevada 2836 83-1614120 (Primary Standard Industrial Classification Code Number) 3475 Edison Way, Suite R Menl ...